Nicholas M Kanaan

List of Publications by Year
in descending order

80	5,637	87723	85405
papers	citations	38 h-index	71 g-index

84	84	84	7415
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Axonal Transport Defects in Neurodegenerative Diseases. Journal of Neuroscience, 2009, 29, 12776-12786.	1.7	398
2	Tau Kinetics in Neurons and the Human Central Nervous System. Neuron, 2018, 97, 1284-1298.e7.	3.8	381
3	Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nature Reviews Neuroscience, 2011, 12, 359-366.	4.9	358
4	Intrastriatal injection of pre-formed mouse Î±-synuclein fibrils into rats triggers Î±-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiology of Disease, 2015, 82, 185-199.	2.1	285
5	Characterization of Prefibrillar Tau Oligomers in Vitro and in Alzheimer Disease. Journal of Biological Chemistry, 2011, 286, 23063-23076.	1.6	281
6	Pathogenic Forms of Tau Inhibit Kinesin-Dependent Axonal Transport through a Mechanism Involving Activation of Axonal Phosphotransferases. Journal of Neuroscience, 2011, 31, 9858-9868.	1.7	231
7	Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. Scientific Reports, 2016, 6, 19393.	1.6	212
8	Liquid-liquid phase separation induces pathogenic tau conformations in vitro. Nature Communications, 2020, 11, 2809.	5.8	200
9	Aging and Parkinson's disease: Different sides of the same coin?. Movement Disorders, 2017, 32, 983-990.	2.2	192
10	Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nature Neuroscience, 2018, 21, 72-80.	7.1	189
11	Axonal degeneration in Alzheimer's disease: When signaling abnormalities meet the axonal transport system. Experimental Neurology, 2013, 246, 44-53.	2.0	171
12	Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration. Journal of Neuroinflammation, 2018, 15, 129.	3.1	131
13	Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Annals of Neurology, 2006, 60, 264-268.	2.8	128
14	Heat Shock Protein 70 Prevents both Tau Aggregation and the Inhibitory Effects of Preexisting Tau Aggregates on Fast Axonal Transport. Biochemistry, 2011, 50, 10300-10310.	1.2	106
15	Soluble pre-fibrillar tau and Î²-amyloid species emerge in early human Alzheimerâ€™s disease and track disease progression and cognitive decline. Acta Neuropathologica, 2016, 132, 875-895.	3.9	105
16	Progression of Tau Pathology in Cholinergic Basal Forebrain Neurons in Mild Cognitive Impairment and Alzheimer's Disease. American Journal of Pathology, 2011, 179, 2533-2550.	1.9	101
17	Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiology of Aging, 2012, 33, 826.e15-826.e30.	1.5	89
18	A Method for Combining RNAscope In Situ Hybridization with Immunohistochemistry in Thick Free-Floating Brain Sections and Primary Neuronal Cultures. PLoS ONE, 2015, 10, e0120120.	1.1	88

#	Article	IF	Citations
19	Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy. Journal of Neuropathology and Experimental Neurology, 2016, 75, 19-34.	0.9	86
20	Interaction of tau with HNRNPA2B1 and N6-methyladenosine RNA mediates the progression of tauopathy. Molecular Cell, 2021, 81, 4209-4227.e12.	4.5	84
21	Axonal Degeneration in Tauopathies: Disease Relevance and Underlying Mechanisms. Frontiers in Neuroscience, 2017, 11, 572.	1.4	82
22	Loss of Functional Alpha-Synuclein: A Toxic Event in Parkinson's Disease?. Journal of Parkinson's Disease, 2012, 2, 249-267.	1.5	72
23	TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	72
24	Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: Relevance to selective neuronal vulnerability. Journal of Comparative Neurology, 2007, 502, 683-700.	0.9	70
25	Pathological conformations involving the amino terminus of tau occur early in Alzheimer's disease and are differentially detected by monoclonal antibodies. Neurobiology of Disease, 2016, 94, 18-31.	2.1	68
26	Calcium dysregulation contributes to neurodegeneration in FTLD patient iPSC-derived neurons. Scientific Reports, 2016, 6, 34904.	1.6	67
27	Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal Î±-synuclein preformed fibrils. Neurobiology of Disease, 2019, 130, 104525.	2.1	67
28	Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys. Neurobiology of Aging, 2010, 31, 937-952.	1.5	60
29	Age and regionâ€specific responses of microglia, but not astrocytes, suggest a role in selective vulnerability of dopamine neurons after 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridine exposure in monkeys. Glia, 2008, 56, 1199-1214.	2.5	57
30	Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicology and Teratology, 2003, 25, 509-517.	1.2	51
31	Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS. Molecular Therapy - Nucleic Acids, 2017, 8, 184-197.	2.3	48
32	Tyrosine Nitration within the Proline-Rich Region of Tau in Alzheimer's Disease. American Journal of Pathology, 2011, 178, 2275-2285.	1.9	46
33	Tau and Axonal Transport Misregulation in Tauopathies. Advances in Experimental Medicine and Biology, 2019, 1184, 81-95.	0.8	46
34	Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease. Brain Research, 2006, 1068, 221-229.	1.1	44
35	Homocysteine Increases Tau Phosphorylation, Truncation and Oligomerization. International Journal of Molecular Sciences, 2018, 19, 891.	1.8	44
36	Rho-kinase ROCK inhibitors reduce oligomeric tau protein. Neurobiology of Aging, 2020, 89, 41-54.	1.5	43

#	Article	IF	Citations
37	Ageâ€related changes in dopamine transporters and accumulation of 3â€nitrotyrosine in rhesus monkey midbrain dopamine neurons: Relevance in selective neuronal vulnerability to degeneration. European Journal of Neuroscience, 2008, 27, 3205-3215.	1.2	41
38	Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition. Neurobiology of Aging, 2016, 47, 113-126.	1.5	41
39	Peroxynitrite-Induced Nitrative and Oxidative Modifications Alter Tau Filament Formation. Biochemistry, 2011, 50, 1203-1212.	1.2	37
40	Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease. Neurobiology of Disease, 2018, 117, 125-136.	2.1	37
41	MDMA administration to pregnant Spragueâ€“Dawley rats results in its passage to the fetal compartment. Neurotoxicology and Teratology, 2006, 28, 459-465.	1.2	36
42	Tau is not necessary for amyloid-Î²â€“induced synaptic and memory impairments. Journal of Clinical Investigation, 2020, 130, 4831-4844.	3.9	34
43	Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2018, 77, 246-259.	0.9	31
44	Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain. Science Translational Medicine, 2019, 11, .	5.8	30
45	Generation of Alpha-Synuclein Preformed Fibrils from Monomers and Use In Vivo. Journal of Visualized Experiments, 2019, , .	0.2	29
46	Tau: A Signaling Hub Protein. Frontiers in Molecular Neuroscience, 2021, 14, 647054.	1.4	29
47	Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport. Experimental Neurology, 2016, 283, 318-329.	2.0	28
48	Production of recombinant tau oligomers in vitro. Methods in Cell Biology, 2017, 141, 45-64.	0.5	28
49	EFhd2 Affects Tau Liquidâ€“Liquid Phase Separation. Frontiers in Neuroscience, 2019, 13, 845.	1.4	28
50	Pioglitazone prevents tau oligomerization. Biochemical and Biophysical Research Communications, 2016, 478, 1035-1042.	1.0	26
51	Gene Therapy Models of Alzheimerâ€™s Disease and Other Dementias. Methods in Molecular Biology, 2016, 1382, 339-366.	0.4	26
52	Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease. Neurobiology of Aging, 2016, 42, 80-90.	1.5	25
53	Neuronal and Glial Distribution of Tau Protein in the Adult Rat and Monkey. Frontiers in Molecular Neuroscience, 2021, 14, 607303.	1.4	25
54	Exposure of the Amino Terminus of Tau Is a Pathological Event in Multiple Tauopathies. American Journal of Pathology, 2017, 187, 1222-1229.	1.9	24

#	Article	IF	Citations
55	Recombinant adenoassociated virus 2/5-mediated gene transfer is reduced in the aged rat midbrain. Neurobiology of Aging, 2015, 36, 1110-1120.	1.5	22
56	Quantitative and semi-quantitative measurements of axonal degeneration in tissue and primary neuron cultures. Journal of Neuroscience Methods, 2016, 266, 32-41.	1.3	21
57	Progression of tau pathology within cholinergic nucleus basalis neurons in chronic traumatic encephalopathy: A chronic effects of neurotrauma consortium study. Brain Injury, 2016, 30, 1399-1413.	0.6	21
58	Tau Phosphorylation is Impacted by Rare AKAP9 Mutations Associated with Alzheimer Disease in African Americans. Journal of NeuroImmune Pharmacology, 2018, 13, 254-264.	2.1	19
59	The Longitudinal Transcriptomic Response of the Substantia Nigra to Intrastriatal 6-Hydroxydopamine Reveals Significant Upregulation of Regeneration-Associated Genes. PLoS ONE, 2015, 10, e0127768.	1.1	18
60	Central role for p62/SQSTM1 in the elimination of toxic tau species in a mouse model of tauopathy. Aging Cell, 2022, 21, .	3.0	17
61	Novel Non-phosphorylated Serine 9/21 GSK3Î²/Î± Antibodies: Expanding the Tools for Studying GSK3 Regulation. Frontiers in Molecular Neuroscience, 2016, 9, 123.	1.4	15
62	Pathogenic tau modifications occur in axons before the somatodendritic compartment in mossy fiber and Schaffer collateral pathways. Acta Neuropathologica Communications, 2019, 7, 29.	2.4	14
63	Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein. International Journal of Molecular Sciences, 2021, 22, 12063.	1.8	10
64	Aging Does Not Affect Axon Initial Segment Structure and Somatic Localization of Tau Protein in Hippocampal Neurons of Fischer 344 Rats. ENeuro, 2017, 4, ENEURO.0043-17.2017.	0.9	9
65	Frontotemporal Lobar Dementia Mutant Tau Impairs Axonal Transport through a Protein Phosphatase 1Î³-Dependent Mechanism. Journal of Neuroscience, 2021, 41, 9431-9451.	1.7	8
66	A human induced pluripotent stem cellâ€derived cortical neuron humanâ€onâ€a chip system to study AÎ² 42 and tauâ€induced pathophysiological effects on longâ€term potentiation. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12029.	1.8	7
67	709. rAAV-Mediated Regulation of Striatal Nurr1 Expression Alters Development and Severity of Levodopa-Induced Dyskinesias in the 6-OHDA Rat Model of Parkinson's Disease. Molecular Therapy, 2015, 23, S282-S283.	3.7	6
68	Syk inhibitor reduces oligomeric tau associated with GSK3Î² inactivation and autophagy activation. Alzheimer's and Dementia, 2020, 16, e042633.	0.4	4
69	EFhd2 brain interactome reveals its association with different cellular and molecular processes. Journal of Neurochemistry, 2021, , .	2.1	4
70	O5â€04â€01: TRIM46 KNOCKDOWN CAUSES NEURONAL TAU REDISTRIBUTION AND INCREASES AXOSOMATIC TAU DIFFUSION. Alzheimer's and Dementia, 2019, 15, .	0.4	3
71	Tau Protein. , 2015, , 857-874.		2
72	Clioquinol reduces tau phosphorylation and oligomerization. Alzheimer's and Dementia, 2020, 16, e044356.	0.4	1

#	Article	IF	Citations
73	P2-056: Differential oligomer formation and phosphatase-activating domain exposure in tau isoforms under reducing and oxidizing conditions in vitro. , 2015, 11, P504-P504.		0
74	[P4â€“090]: THE SUBCELLULAR LOCALIZATION OF TAU AND THE PROPERTIES OF MUTANT P301L TAU IN PRIMARY NEURON CULTURES. Alzheimer's and Dementia, 2017, 13, P1293.	0.4	0
75	[O2â€“03â€“03]: TAUâ€INDUCED NEURODEGENERATION IS MEDIATED BY RNA BINDING PROTEINS. Alzheimer's and Dementia, 2017, 13, P555.	0.4	0
76	P3â€•181: THE INTERACTION BETWEEN TAU AND PROTEIN PHOSPHATASE 1 IS AFFECTED BY P301L MUTATION. Alzheimer's and Dementia, 2018, 14, P1136.	0.4	0
77	O3â€01â€03: TAU KINETICS IN NEURONS AND IN THE HUMAN CNS. Alzheimer's and Dementia, 2018, 14, P1008.	0.4	0
78	SPRR1A expression in experimental Osteoarthritis. Is there a role in pain?. Frontiers in Cellular Neuroscience, 0, 13, .	1.8	0
79	HNRNPA2B1 Mediates the Association of Oligomeric Tau with N ⁶-Methyladenosine and Neurodegeneration. SSRN Electronic Journal, 0, , .	0.4	0
80	A Complex Containing HNRNPA2B1 and N ⁶-Methyladenosine Modified Transcripts Mediates Actions of Toxic Tau Oligomers. SSRN Electronic Journal, 0, , .	0.4	0